Henrik Ibsen’s 19th-century play An Enemy of the People dramatizes a timeless public health dilemma: when community health conflicts with economic interests, which prevails? The Norwegian playwright’s protagonist, Dr. Stockmann, discovers biological contamination in the town’s public baths—a major tourist attraction and economic engine. His recommendation to close the baths for remediation is rejected by local authorities who prioritize financial revenue over population health. More than a century later, this tension between liberal market economics and health equity remains unresolved in modern healthcare systems.
Key takeaways
- Economic interests have historically overridden public health recommendations, from Ibsen’s fictional baths to contemporary healthcare access disparities
- Liberal economic frameworks often treat health as a commodity rather than a fundamental right, limiting equitable access
- Structural reforms requiring regulation and universal health coverage models offer pathways to align economic systems with health equity principles
The dilemma that Ibsen posed remains central to modern health policy debates. Health policy frameworks worldwide continue to grapple with the same question: should markets and profit motives shape healthcare access, or should governments mandate equitable coverage regardless of economic cost?
The historical pattern: profit over protection
Ibsen’s narrative, though fictional, reflects documented patterns in public health history. From 19th-century industrial sanitation reforms delayed by factory owners to contemporary pharmaceutical pricing disputes, economic actors have repeatedly resisted health interventions that threatened profitability. The play’s central tragedy is not the contamination itself, but society’s collective choice to ignore it.
This dynamic persists in modern healthcare systems, particularly in countries relying heavily on private markets. Global health inequities—including unequal access to vaccines, medicines, and basic care—reflect structural choices where profit maximization takes precedence over universal health coverage. Low- and middle-income countries face the starkest versions of this conflict, where pharmaceutical corporations charge prices beyond what populations can afford, and health systems lack resources to provide care regardless of ability to pay.
Liberal economics and the commodification of health
Liberal market theory treats healthcare as a commodity subject to supply-and-demand pricing, similar to consumer goods. Under this framework, those who can afford care receive it; those who cannot are left unserved. This logic directly contradicts the principle of health equity—the idea that health status should not be determined by wealth or social position.
The tension emerges because health is fundamentally different from other commodities. Disease does not discriminate by income; infectious outbreaks spread across economic classes. Untreated illness in poor populations creates public health hazards affecting everyone, including the wealthy. Yet purely market-based systems create powerful incentives to underprovide care to unprofitable populations—precisely those most vulnerable to disease.
The core conflict is not between health and economics, but between two visions of economics: one that treats health as a private good subject to market forces, and one that treats health as a public good requiring collective investment and universal access.
— Perspective piece, The Lancet (2026)
What universal coverage reveals: aligning systems with equity
Countries that have implemented universal health coverage models—whether through single-payer systems, social insurance, or heavily subsidized public schemes—have demonstrated that equitable access is economically achievable. Health equity frameworks require regulatory intervention: governments must set drug prices, mandate coverage standards, and redistribute resources to underserved populations. These moves directly constrain profit maximization in certain sectors.
The evidence is clear: systems that prioritize equity outcomes (measured by population health gains, reduced disparities, financial protection) require deliberate policy choices against unfettered market logic. This does not mean eliminating markets or innovation incentives, but rather embedding them within regulatory structures that prevent market failures in essential health services.
What this means
The choice remains ours
Ibsen’s Dr. Stockmann was ultimately vindicated: the contamination was real, the health threat was genuine, and closing the baths was the correct public health decision. The tragedy was not the recommendation, but society’s delay in acting on it. Modern health systems face the same choice, not in singular dramatic moments, but continuously through policy decisions on pricing, coverage, and resource allocation.
The economic systems that govern healthcare are human constructions, not natural laws. They can be reformed. Countries increasingly recognize that health equity requires deliberate structural change—universal coverage expansions, price regulation, progressive taxation to fund public health—precisely because market forces alone do not produce equitable outcomes. The question is not whether economics and health equity can coexist, but whether societies have the political will to reform economic structures to serve health as a public good.
Source: Perspective: Liberalism and health equity?, The Lancet (2026)
Was this article helpful?
Related Coverage
